Reliability parameters for SMA patients.

<p>** p-value < 0.01.</p><p>Reliability parameters for SMA patients.</p

Correlation between MyoSets at baseline on dominant (D) and non-dominant (ND) sides, clinical and motor function parameters.

<p>* p-value < 0.05,</p><p>** p-value < 0.01.</p><p>Correlation between MyoSets at baseline on dominant (D) and non-dominant (ND) sides, clinical and motor function parameters.</p

Clinical data of all SMA patients sorted by age.

<p>FVC—Forced vital capacity (% of predicted values), NNV—nasal nocturnal ventilation, NA- not available.</p><p>Clinical data of all SMA patients sorted by age.</p

MoviPlate correlations with grip and pinch strength.

<p>Correlations at baseline between the MoviPlate scores and grip and pinch strength for all SMA patients for the non-dominant hands (dark dots) and the dominant hands (clear dots).</p

Comparison of strength and motor function between the two groups on dominant (D) and non-dominant (ND) sides.

<p>* p-value < 0.05 for group effect,</p><p>** p-value < 0.01 for group effect.</p><p>Comparison of strength and motor function between the two groups on dominant (D) and non-dominant (ND) sides.</p

Follow-up MyoSets data and MFM scores for all SMA patients.

<p>Data at 6 months and at one year for all SMA patients for (A) grip, (B) pinch, and (C) MoviPlate on the dominant (D) and non-dominant (ND) sides and for (D) MFM-D3 and MFM-Total scores. SMA type II for whom data at 6 months and one year are lacking are marked with orange triangles; for type II patients for whom data were obtained at both time points, the orange interrupted line represents their evolution. The purple solid lines represent the evolution of SMA type 3 patients. The age of 14 is marked with a vertical dotted line.</p

Reliability test.

<p>Reliability of test and retest sessions for (A) grip, (B) pinch, and (C) MoviPlate for all SMA patients for the non-dominant hands (dark dots) and the dominant hands (clear dots).</p

Clinical and functional comparison between the SMA type II and III groups.

<p>* p-value < 0.05 for group effect,</p><p>** p-value < 0.01 for group effect.</p><p>Clinical and functional comparison between the SMA type II and III groups.</p

MyoSets and MFM evolution at one year follow-up on dominant (D) and non-dominant (ND) sides for all SMA patients, with a cutoff at 14 years.

<p>* p-value < 0.05.</p><p>MyoSets and MFM evolution at one year follow-up on dominant (D) and non-dominant (ND) sides for all SMA patients, with a cutoff at 14 years.</p

Clinical and functional data at baseline.

<p>Clinical and functional data at baseline.</p